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Development of a Clinical Pathway for the Whipple Procedure
• By standardizing health care services in the most 
efficient, safe, and cost-effective way, clinical pathways 
can be successful in driving healthcare towards the 
goals of the Triple Aim.
• Patients who undergo a pancreaticoduodenectomy are 
at a high risk for post-operative complications due to 
the radical nature of the procedure and the 
circumstances under which they receive this 
procedure.
• A patient typically undergoes a Whipple procedure if 
they are diagnosed with a cancer that resides within 
the head of the pancreas, ampulla of Vater, the lower 
end of the common bile duct, or the duodenum. 
• During a standard Whipple procedure the head of the 
pancreas, the gallbladder, a portion of the common bile 
duct, the duodenum, and the pylorus of the stomach 
are all removed.
• The purpose of this investigation was to see how the 
development of a clinical pathway for the Whipple 
procedure could be beneficial to patients and  LVHN.
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• No patient outcome statistics were produced.
• This was due to the lack of a sufficient amount 
of time to collect these measures of data after 




1. Day of nasogastric  tube 
removal
2. Day of discharge
3. 30-day mortality rate
4. 30-day readmission rate









• Other studies with similar pathways showed 
great success in adhering to pathway standards 
while maintaining patient outcomes.
• University of Virginia (113 patient study): 
– Post-Op Day 3 NG tube removal = 93.0%
– Post-Op Day 6 discharge = 35.4%
– 30-day mortality rate = 0%
– 30-day readmission rate = 15.9%
– Post-operative morbidity = 48.7%
• An all-encompassing clinical pathway for the 
Whipple procedure was produced.
• Upon further investigation and data collection, 
the institution of this clinical pathway may prove 
to be beneficial to its affected patients and 
Lehigh Valley Health Network itself, achieving 
the goals set by the Triple Aim.  
• Success of other investigations involving clinical 
pathways demonstrates the significance in 
continuing the development of clinical pathways 
for other procedures.
• Clinical pathways naturally lend themselves to 
constant reevaluation and further improvement.
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-Malnutrition screening, appropriate assignment of nutritional  
supplements (Ensures)
-Patient education on diet and nutrition; Dietary Manual, The 
Pancreatic Cancer Diet Education Booklet, Nutrition and Symptom 






-Epidural placed (T8-12 dermatomal distribution) 
-NG tube placed
-Pre-incision antibiotics
-Sequential compression devices and spongy pad placed
-Standard pancreaticoduodenectomy 
-PACU recovery
-Transfer to surgical floor or ICU
-NPO, ice chips ad lib
-Administer protonix (PPI)
-Antibiotics x 24 hrs for patients with pre-operative stents
-Bolus with colloid or crystallite; Ringers lactate 150 ml/hour
-Within 24 hours, basic mobility screening 
Post-Op 
Day 1
-Move patient to sit in chair
-NPO, ice chips ad lib
-Switch IV to dextrose fluid
-SQ Heparin 
-Schedule post-op cardiac consult if needed
Post-Op 
Day 2
-Basic Mobility screening (PT consult or mobilized immediately)




-IV morphine after removal of epidural
-6 hours later, remove Foley catheter 
-Remove NG tube
-Ice chips ad lib and sips of water
Post-Op 
Day 4
-Clear liquids, nutritional supplement (Ensure Enlive)
-Percocet administration (1 at a time)
Post-Op 
Day 5
-Clear liquids, nutritional supplement (Ensure Enlive)
-Percocet administration (1 at a time)
Post-Op 
Day 6
-Discharge on PPI 
-Schedule surgical follow up in 1 week
-Resume regular diet
-Drain management (on per case basis)
